These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Paintal A; Raparia K; Zakowski MF; Nayar R Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177 [TBL] [Abstract][Full Text] [Related]
27. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663 [TBL] [Abstract][Full Text] [Related]
28. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203 [TBL] [Abstract][Full Text] [Related]
29. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Rakha EA; Patil S; Abdulla K; Abdulkader M; Chaudry Z; Soomro IN Diagn Cytopathol; 2010 Dec; 38(12):874-9. PubMed ID: 20049969 [TBL] [Abstract][Full Text] [Related]
30. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods. Sule Kutlar Dursun F; Alabalik U Pol J Pathol; 2022; 73(2):111-119. PubMed ID: 36172747 [TBL] [Abstract][Full Text] [Related]
31. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166 [TBL] [Abstract][Full Text] [Related]
33. Primary pleural epithelioid mesothelioma of clear cell type: a case report and review of current literature. Gkogkou C; Samitas K; Foteinou M Ultrastruct Pathol; 2011 Dec; 35(6):267-70. PubMed ID: 21978187 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025 [TBL] [Abstract][Full Text] [Related]
35. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma. Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772 [TBL] [Abstract][Full Text] [Related]